CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty CLDF Committees 2022 GI Fellow Board of Advisors
Embassy of Education  
Slide Library Publications Webcasts Abstract Library Committee Members
 
NASH | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
1.The Role of Growth Hormone and Insulin Growth Factor 1 in the Development of Non-Alcoholic Steato-Hepatitis: A Systematic Review
 

Cells. 2023 Feb 4;12(4):517. doi: 10.3390/cells12040517.

Luca Cristin 1, Amalia Montini 2, Alessandro Martinino 3, Juan Pablo Scarano Pereira 4, Francesco Giovinazzo 5, Salvatore Agnes 5
 
2.A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis
 

Hepatol Commun. 2023 Feb 9;7(3):e0036. doi: 10.1097/HC9.0000000000000036.eCollection 2023 Mar 1.

Mark G Swain 1, Billie Pettersson 2, Oren Meyers 3, Meredith Venerus 4, Jan Oscarsson 5
 
3.NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
 

Intern Emerg Med. 2023 Feb 17. doi: 10.1007/s11739-023-03203-0.Online ahead of print.

Piero Portincasa 1
 
4.Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties
 

J Hepatol. 2023 Feb 3;S0168-8278(23)00079-X. doi: 10.1016/j.jhep.2023.01.026.Online ahead of print.

Alina M Allen 1, Jeffrey V Lazarus 2, Zobair M Younossi 3
 
5.Nonalcoholic fatty liver disease from a primary care perspective
 

Diabetes Obes Metab. 2023 Feb 15. doi: 10.1111/dom.15016. Online ahead of print.

Jeanne M Clark 1, Donna R H Cryer 2, Michelle Morton 3, Jay H Shubrook 4
 
6.The role of hepatokines in NAFLD
 

Cell Metab. 2023 Feb 7;35(2):236-252. doi: 10.1016/j.cmet.2023.01.006.

Norbert Stefan 1, Fritz Schick 2, Andreas L Birkenfeld 3, Hans-Ulrich Häring 3, Morris F White 4
 
7.Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat
 

Clin Gastroenterol Hepatol. 2023 Jan;21(1):143-152.e3.doi: 10.1016/j.cgh.2021.12.044. Epub 2022 Jan 6.

Eric J Lawitz 1, Bal Raj Bhandari 2, Peter J Ruane 3, Anita Kohli 4, Eliza Harting 5, Dora Ding 5, Jen-Chieh Chuang 5, Ryan S Huss 5, Chuhan Chung 5, Robert P Myers 5, Rohit Loomba 6
 
8.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
 

Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000004. Online ahead of print.

Zobair M Younossi 1 2 3, Pegah Golabi 1 2 3, James M Paik 1 2 3, Austin Henry 1, Catherine Van Dongen 1, Linda Henry 1 2 3
 
9.Genome Editing and Fatty Liver
 

Adv Exp Med Biol. 2023;1396:191-206. doi: 10.1007/978-981-19-5642-3_13.

Umar Hayat 1, Ali A Siddiqui 2, Muhammad L Farhan 3, Ahmed Haris 4, Nasir Hameed 5
 
10.Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
 

Aliment Pharmacol Ther. 2023 Jan;57(1):37-51. doi: 10.1111/apt.17292.Epub 2022 Nov 9.

Maral Amangurbanova 1, Daniel Q Huang 1 2 3, Rohit Loomba 1 4
 
11.A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
 

JHEP Rep. 2022 Aug 23;5(1):100563. doi: 10.1016/j.jhepr.2022.100563. eCollection 2023 Jan.

Stephen A Harrison 1, Peter J Ruane 2, Bradley Freilich 3, Guy Neff 4, Rashmee Patil 5, Cynthia Behling 6, Chen Hu 7, Reshma Shringarpure 8, Brittany de Temple 8, Erica Fong 8, Erik J Tillman 8, Timothy Rolph 8, Andrew Cheng 8, Kitty Yale 8
 
12.Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients
 

Acta Pharm Sin B. 2023 Jan;13(1):1-28. doi: 10.1016/j.apsb.2022.08.018.Epub 2022 Aug 28.

Solène Marie 1, Kayla L Frost 1, Raymond K Hau 1, Lucy Martinez-Guerrero 1, Jailyn M Izu 1, Cassandra M Myers 1, Stephen H Wright 2, Nathan J Cherrington 1
 
13.A multistakeholder approach to innovations in NAFLD care
 

Commun Med (Lond)\. 2023 Jan 3;3(1):1. doi: 10.1038/s43856-022-00228-y.

Jörn M Schattenberg 1, Alina M Allen 2, Helen Jarvis 3, Shira Zelber-Sagi 4 5, Ken Cusi 6, John F Dillon 7, Cyrielle Caussy 8 9, Sven M Francque 10 11, Zobair Younossi 12, Naim Alkhouri 13, Jeffrey V Lazarus 14 15 16
 
14.Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
 

Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30.doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16.

Jingxuan Quek 1, Kai En Chan 1, Zhen Yu Wong 2, Caitlyn Tan 1, Bryan Tan 1, Wen Hui Lim 1, Darren Jun Hao Tan 1, Ansel Shao Pin Tang 1, Phoebe Tay 1, Jieling Xiao 1, Jie Ning Yong 1, Rebecca Wenling Zeng 1, Nicholas W S Chew 3, Benjamin Nah 4, Anand Kulkarni 5, Mohammad Shadab Siddiqui 6, Yock Young Dan 7, Vincent Wai-Sun Wong 8, Arun J Sanyal 6, Mazen Noureddin 9, Mark Muthiah 10, Cheng Han Ng 1
 
15.Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity
 

Front Endocrinol (Lausanne). 2023 Jan 17;14:1062341.doi: 10.3389/fendo.2023.1062341. eCollection 2023.

Emiliano Barbieri 1, Nicola Santoro 2 3 4, Giuseppina Rosaria Umano 5
 
16.The Non-Invasive Assessment of Circulating D-Loop and mt-ccf Levels Opens an Intriguing Spyhole into Novel Approaches for the Tricky Diagnosis of NASH
 

Int J Mol Sci. 2023 Jan 24;24(3):2331. doi: 10.3390/ijms24032331.

Erika Paolini 1 2, Miriam Longo 1 3, Alberto Corsini 2 4, Paola Dongiovanni 1
 
17.Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials
 

Clin Gastroenterol Hepatol. 2023 Jan;21(1):90-102.e6.doi: 10.1016/j.cgh.2022.01.015. Epub 2022 Jan 22.

Vincent Wai-Sun Wong 1, Won Young Tak 2, George Boon Bee Goh 3, Pin-Nan Cheng 4, Eric J Lawitz 5, Zobair M Younossi 6, Raj Vuppalanchi 7, Ziad Younes 8, Naim Alkhouri 9, Lulu Wang 10, Jialuo Liu 10, Kathryn Kersey 10, Robert P Myers 10, Stephen A Harrison 11, Zachary Goodman 6, Michael Trauner 12, Manuel Romero-Gomez 13, Quentin M Anstee 14, Mindie H Nguyen 15, Takeshi Okanoue 16
 
18.The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care
 

Hepatology. 2023 Jan 1;77(1):256-267. doi: 10.1002/hep.32545.Epub 2022 May 24.

Pimsiri Sripongpun 1 2, W Ray Kim 1, Ajitha Mannalithara 1, Vivek Charu 3 4, Anna Vidovszky 1, Steven Asch 5, Manisha Desai 4, Sun H Kim 6 7, Allison J Kwong 1
 
19.Relationship between NAFLD and coronary artery disease: A Mendelian randomization study
 

Hepatology. 2023 Jan 1;77(1):230-238. doi: 10.1002/hep.32534. Epub 2022 May 18.

Zhewen Ren 1 2 3, Pomme I H G Simons 1 2 3, Anke Wesselius 4 5, Coen D A Stehouwer 2 3 6, Martijn C G J Brouwers 1 3
 
20.MAFLD and Celiac Disease in Children
 

Int J Mol Sci. 2023 Jan 16;24(2):1764. doi: 10.3390/ijms24021764.

Serena Scapaticci 1, Annamaria Venanzi 1, Francesco Chiarelli 1, Cosimo Giannini 1
 
21.Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
 

World J Gastroenterol. 2023 Jan 14;29(2):367-377. doi: 10.3748/wjg.v29.i2.367.

Christoph G Dietrich 1, Andreas Geier 2, Uta Merle 3
 
22.Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review
 

Semin Arthritis Rheum. 2023 Jan 18;59:152165.doi: 10.1016/j.semarthrit.2023.152165. Online ahead of print.

Kelly Torosian 1, Esha Lal 1, Arthur Kavanaugh 2, Rohit Loomba 3, Veeral Ajmera 4, Monica Guma 5
 
23.Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
 

iScience. 2022 Dec 30;26(1):105905. doi: 10.1016/j.isci.2022.105905.eCollection 2023 Jan 20.

Gideon G Kang 1, Natalie L Trevaskis 1, Andrew J Murphy 2, Mark A Febbraio 1
 
24.Rational Combination Therapy for NASH: Insights from Clinical Trials and Error
 

J Hepatol. 2023 Jan 2;S0168-8278(22)03477-8. doi: 10.1016/j.jhep.2022.12.025.Online ahead of print.

Vlad Ratziu 1, Michael Charlton 2
 
25.Inflammatory processes involved in NASH-related hepatocellular carcinoma
 

Biosci Rep. 2023 Jan 31;43(1):BSR20221271. doi: 10.1042/BSR20221271.

Stefania Cannito 1, Umberto Dianzani 2, Maurizio Parola 1, Emanuele Albano 2, Salvatore Sutti 2
 
26.Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
 

Nutrients. 2023 Jan 29;15(3):687. doi: 10.3390/nu15030687.

Daniel Clayton-Chubb 1 2, William Kemp 1 2, Ammar Majeed 1 2, John S Lubel 1 2, Alex Hodge 3 4, Stuart K Roberts 1 2
 
27.MAFLD: a multisystem disease
 

Ther Adv Endocrinol Metab. 2023 Jan 28;14:20420188221145549.doi: 10.1177/20420188221145549. eCollection 2023.

Rosaria Maria Pipitone 1, Carlo Ciccioli 1, Giuseppe Infantino 1, Claudia La Mantia 1, Stefanie Parisi 1, Adele Tulone 1, Grazia Pennisi 1, Stefania Grimaudo 1, Salvatore Petta 2 1
 
28.NAFLD as the metabolic hallmark of obesity
 

Intern Emerg Med. 2023 Jan;18(1):31-41. doi: 10.1007/s11739-022-03139-x.Epub 2022 Nov 10.

Alba Rojano # 1, Elena Sena # 2, Ramiro Manzano-Nuñez 2, Juan M Pericàs 3 4, Andreea Ciudin 5 6 7 8
 
29.High-Intensity Interval Training is Safe, Feasible and Efficacious in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
 

Dig Dis Sci. 2022 Dec 20;1-17. doi: 10.1007/s10620-022-07779-z. Online ahead of print.

Shelley E Keating 1, Ilaria Croci 2 3 4, Matthew P Wallen 5 6, Emily R Cox 7, Moe Thuzar 8 9, Uyen Pham 10 11 12, Gregore I Mielke 13, Jeff S Coombes 2, Graeme A Macdonald 12 14, Ingrid J Hickman 12 15
 
30.A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis
 

Aliment Pharmacol Ther. 2023 Feb;57(3):304-312. doi: 10.1111/apt.17346. Epub 2022 Dec 13.

Zobair Younossi 1 2 3, Naim Alkhouri 4, Ken Cusi 5, Scott Isaacs 6, Fasiha Kanwal 7, Mazen Noureddin 8, Rohit Loomba 9, Natarajan Ravendhran 10, Brian Lam 2 3, Khalil Nader 11 12, Andrei Racila 2 3 12, Fatema Nader 12, Linda Henry 2 3 12
 
31.Nonheavy Alcohol Use Associates With Liver Fibrosis and Nonalcoholic Steatohepatitis in the Framingham Heart Study
 

Clin Gastroenterol Hepatol. 2022 Dec 8;S1542-3565(22)01125-9. doi: 10.1016/j.cgh.2022.10.039.Online ahead of print.

Brooke A Rice 1, Timothy S Naimi 2, Michelle T Long 3
 
32.Trends in prevalence of probable fibrotic non-alcoholic steatohepatitis in the United States, 1999-2016
 

Liver Int. 2023 Feb;43(2):340-344. doi: 10.1111/liv.15503. Epub 2022 Dec 30.

Stefano Ciardullo 1 2, Gianluca Perseghin 1 2
 
33.NAFLD and type 2 diabetes: A practical guide for the joint management
 

Gastroenterol Hepatol. 2022 Dec 27;S0210-5705(22)00311-9.doi: 10.1016/j.gastrohep.2022.12.002. Online ahead of print.

Idoia Genua 1, Paula Iruzubieta 2, Juan Carlos Rodríguez-Duque 2, Antonio Pérez 3, 
 
34.Non-alcoholic fatty liver disease-A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease
 

Front Physiol. 2022 Dec 15;13:963513. doi: 10.3389/fphys.2022.963513. eCollection 2022.

Joanne Watt 1, Mary Jo Kurth 1, Cherith N Reid 1, John V Lamont 1, Peter Fitzgerald 1, Mark W Ruddock 1
 
35.Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999-2016
 

Clin Gastroenterol Hepatol. 2022 Dec;20(12):2838-2847.e7. doi: 10.1016/j.cgh.2021.12.015.Epub 2021 Dec 17.

Pegah Golabi 1, James M Paik 1, Michael Harring 2, Elena Younossi 3, Khaled Kabbara 1, Zobair M Younossi 4
 
36.Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent
 

Nutr Metab Cardiovasc Dis. 2022 Dec 21;S0939-4753(22)00496-3.doi: 10.1016/j.numecd.2022.12.010. Online ahead of print.

Santo Colosimo 1, Garry D Tan 2, Maria Letizia Petroni 3, Giulio Marchesini 3, Jeremy W Tomlinson 4
 
37.Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease
 

Gut. 2022 Dec 15;gutjnl-2022-328105. doi: 10.1136/gutjnl-2022-328105. Online ahead of print.

Tracey G Simon 1, Bjorn Roelstraete 2, Naim Alkhouri 3, Hannes Hagström 2 4, Johan Sundström 5, Jonas F Ludvigsson 6 7
 
38.Upper gut heat shock proteins HSP70 and GRP78 promote insulin resistance, hyperglycemia, and non-alcoholic steatohepatitis
 

Nat Commun. 2022 Dec 13;13(1):7715. doi: 10.1038/s41467-022-35310-5.

Giulia Angelini 1 2, Lidia Castagneto-Gissey 3, Serenella Salinari 4, Alessandro Bertuzzi 5, Danila Anello 1, Meenakshi Pradhan 6, Marlen Zschätzsch 7 8, Paul Ritter 9, Carel W Le Roux 10, Francesco Rubino 11, Nicola Basso 3, Giovanni Casella 3, Stefan R Bornstein 12 13, Valentina Tremaroli 6, Geltrude Mingrone 14 15 16
 
39.Obesity, but not glycemic control, predicts liver steatosis in children with type 1 diabetes
 

Emir Tas 1, Shasha Bai 2, Daniel Mak 3, Eva C Diaz 4, Jonathan A Dranoff 5

J Diabetes Complications. 2022 Dec;36(12):108341. doi: 10.1016/j.jdiacomp.2022.108341.Epub 2022 Oct 25.
 
40.Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders
 

Curr Gastroenterol Rep. 2022 Dec 5. doi: 10.1007/s11894-022-00859-0.Online ahead of print.

Senthilkumar Sankararaman 1, Kimberly Noriega 2, Sujithra Velayuthan 3, Thomas Sferra 3, Robert Martindale 4
 
41.Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration
 

Nutrients. 2022 Dec 15;14(24):5340. doi: 10.3390/nu14245340.

Andrea Peloso 1, Matthieu Tihy 2 3, Beat Moeckli 1, Laura Rubbia-Brandt 2 3, Christian Toso 1
 
42.Understanding gut-liver axis nitrogen metabolism in Fatty Liver Disease
 

Front Endocrinol (Lausanne). 2022 Dec 15;13:1058101.doi: 10.3389/fendo.2022.1058101. eCollection 2022.

Teresa C Delgado 1 2, Javier de Las Heras 2 3 4, María L Martínez-Chantar 1 5
 
43.Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis
 

Clin Pharmacol Ther. 2022 Dec;112(6):1271-1279. doi: 10.1002/cpt.2745.Epub 2022 Sep 27.

Atoosa Rabiee # 1, Martha D Gay # 2, Narayan Shivapurkar 2, Hong Cao 2, Sandeep Nadella 3, Coleman I Smith 3, James H Lewis 3, Sunil Bansal 2, Amrita Cheema 2, John Kwagyan 4, Jill P Smith 1 2
 
44.Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH
 

Expert Opin Investig Drugs. 2022 Dec 28;1-10. doi: 10.1080/13543784.2022.2159804.Online ahead of print.

David A Fraser 1, Stephen A Harrison 1 2, Detlef Schuppan 3 4
 
45.Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment
 

J Clin Transl Hepatol. 2023 Apr 28;11(2):502-515. doi: 10.14218/JCTH.2022.00204.Epub 2022 Dec 23.

Ankoor H Patel 1 2, Dhiraj Peddu 1 2, Sahil Amin 1 2, Mohamed I Elsaid 3 4, Carlos D Minacapelli 1 2, Toni-Marie Chandler 1 2, Carolyn Catalano 1 2, Vinod K Rustgi 1 2
 
46.Non-Alcoholic Fatty Liver Disease, Heart Failure, and Long-Term Mortality: Insights From the National Health and Nutrition Examination Survey
 

Curr Probl Cardiol. 2022 Dec;47(12):101333. doi: 10.1016/j.cpcardiol.2022.101333.Epub 2022 Jul 25.

Abdul Mannan Khan Minhas 1, Vardhmaan Jain 2, Muhammad Haisum Maqsood 3, Ambarish Pandey 4, Sadiya S Khan 5, Marat Fudim 6, Gregg C Fonarow 7, Javed Butler 8, Muhammad Shahzeb Khan 9
 
47.Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial
 

Ann Intern Med. 2023 Jan;176(1):10-21. doi: 10.7326/M22-1787.Epub 2022 Dec 13.

Camilla Dalby Hansen 1, Eva-Marie Gram-Kampmann 2, Johanne Kragh Hansen 3, Mie Balle Hugger 1, Bjørn Stæhr Madsen 3, Jane Møller Jensen 3, Sara Olesen 3, Nikolaj Torp 1, Ditlev Nytoft Rasmussen 3, Maria Kjærgaard 1, Stine Johansen 1, Katrine Prier Lindvig 4, Peter Andersen 3, Katrine Holtz Thorhauge 1, Jan Christian Brønd 5, Pernille Hermann 6, Henning Beck-Nielsen 2, Sönke Detlefsen 7, Torben Hansen 8, Kurt Højlund 2, Maja Sofie Thiele 1, Mads Israelsen 3, Aleksander Krag 9
 
48.SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum
 

J Gastroenterol. 2022 Dec 5;1-19. doi: 10.1007/s00535-022-01932-1.Online ahead of print.

Yoshihiro Kamada 1, Takahiro Nakamura 2, Satoko Isobe 3, Kumiko Hosono 4, Yukiko Suama 5, Yukie Ohtakaki 6, Arihito Nauchi 7, Naoto Yasuda 8, Soh Mitsuta 3, Kouichi Miura 9, Takuma Yamamoto 10, Tatsunori Hosono 11, Akihiro Yoshida 12, Ippei Kawanishi 13, Hideaki Fukushima 14, Masao Kinoshita 15, Atsushi Umeda 16, Yuichi Kinoshita 17, Kana Fukami 18, Toshio Miyawaki 5, Hideki Fujii 19, Yuichi Yoshida 20, Miwa Kawanaka 21, Hideyuki Hyogo 22 23, Asahiro Morishita 24, Hideki Hayashi 25, Hiroshi Tobita 26, Kengo Tomita 27, Tadashi Ikegami 28, Hirokazu Takahashi 29, Masato Yoneda 30, Dae Won Jun 31, Yoshio Sumida 32, Takeshi Okanoue 33, Atsushi Nakajima 30; JANIT Forum
 
49.Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
 

Int J Mol Sc. 2022 Dec 19;23(24):16226. doi: 10.3390/ijms232416226.

Stephen D H Malnick 1, Pavel Alin 1, Marina Somin 1, Manuela G Neuman 2
 
50.Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes
 

J Comp Eff Res. 2022 Dec;11(18):1349-1363. doi: 10.2217/cer-2021-0194. Epub 2022 Nov 1.

William L Herring 1, Ian Gopal Gould 1, Villum Wittrup-Jensen 2, Judith Ertle 2, Effie Kuti 3, Sorrel Wolowacz 4
 
51.Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
 

Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132.doi: 10.1016/S2468-1253(22)00347-8. Epub 2022 Dec 12.

Rohit Loomba 1, Eric J Lawitz 2, Juan Pablo Frias 3, Grisell Ortiz-Lasanta 4, Lars Johansson 5, Bridgette Boggess Franey 6, Linda Morrow 7, Moti Rosenstock 8, Cynthia L Hartsfield 9, Chao-Yin Chen 9, Leo Tseng 9, R Will Charlton 9, Hank Mansbach 9, Maya Margalit 10
 
52.Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial
 

Cell Metab. 2023 Jan 3;35(1):56-70.e3.doi: 10.1016/j.cmet.2022.12.001. Epub 2022 Dec 21.

Mark Ezpeleta 1, Kelsey Gabel 1, Sofia Cienfuegos 1, Faiza Kalam 1, Shuhao Lin 1, Vasiliki Pavlou 1, Zhenyuan Song 1, Jacob M Haus 2, Sean Koppe 3, Shaina J Alexandria 4, Lisa Tussing-Humphreys 1, Krista A Varady 5
 
53.Eating, diet, and nutrition for the treatment of NAFLD
 

Clin Mol Hepatol. 2022 Dec 14. doi: 10.3350/cmh.2022.0364. Online ahead of print.

Georg Semmler 1, Christian Datz 2, Michael Trauner 1
 
54.A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers
 

Panminerva Med. 2022 Dec;64(4):485-496.doi: 10.23736/S0031-0808.22.04590-6. Epub 2022 Apr 19.

Nuria Perez-Diaz-Del-Campo 1, Jose I Riezu-Boj 1 2, Bertha A Marin-Alejandre 1, J Ignacio Monreal 2 3, Mariana Elorz 2 4, José I Herrero 2 5 6, Alberto Benito-Boillos 2 4, Fermín I Milagro 1 2 7, Elisabetta Bugianesi 8, Josep A Tur 7 9, J Alfredo Martinez 10 2 7, Itziar Abete 1 2 7, M Angeles Zulet 1 2 7
 
55.Clinical features and management issues of NAFLD-related HCC: what we know so far
 

Expert Rev Gastroenterol Hepatol. 2023 Jan;17(1):31-43.doi: 10.1080/17474124.2023.2162503. Epub 2022 Dec 28.

Nicola Pugliese 1 2, Ludovico Alfarone 2, Ivan Arcari 2, Silvia Giugliano 3, Tommaso Lorenzo Parigi 2, Maria Rescigno 2 3, Ana Lleo 1 2, Alessio Aghemo 1 2
 
56.Pre-emptive TIPSS in Acute Variceal Bleeding: Current Status, Controversies, and Future Directions
 

J Clin Transl Hepatol. 2022 Dec 28;10(6):1223-1228.doi: 10.14218/JCTH.2022.00240. Epub 2022 Jul 29.

Yu Jun Wong 1 2, Wei Ling Danielle Ho 1, Juan G Abraldes 3
 
57.Liver Transplantation for NAFLD: indications and post-transplant management
 

Clin Mol Hepatol. 2022 Dec 28. doi: 10.3350/cmh.2022.0392. Online ahead of print.

Sara Battistella 1, Francesca D'Arcangelo 1, Marco Grasso 1, Alberto Zanetto 1, Martina Gambato 1, Giacomo Germani 1, Marco Senzolo 1, Francesco Paolo Russo 1, Patrizia Burra 1
 
58.Identification of high-risk subjects in NAFLD
 

Clin Mol Hepatol. 2022 Dec 5. doi: 10.3350/cmh.2022.0431. Online ahead of print.

Christiane Stern 1, Laurent Castera 1 2
 
59.Bariatric surgery for NAFLD: Indications and post-operative management
 

Clin Mol Hepatol. 2022 Dec 22. doi: 10.3350/cmh.2022.0373. Online ahead of print.

Geerts Anja 1 2, Sander Lefere 2
 
60.Is your patient at risk for NAFLD?
 

Cleve Clin J Med. 2022 Dec 1;89(12):719-727. doi: 10.3949/ccjm.89a.22005.

Patress Ann Persons 1, Sophie Bersoux 2, Mary Helen Whited 3
 
61.Gut-Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome
 

Biology (Basel). 2022 Nov 6;11(11):1622. doi: 10.3390/biology11111622.

Salvatore Pezzino 1, Maria Sofia 1, Gloria Faletra 1, Chiara Mazzone 1, Giorgia Litrico 1, Gaetano La Greca 1, Saverio Latteri 1
 
62.The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review
 

Nutrients. 2022 Nov 3;14(21):4655. doi: 10.3390/nu14214655.

Celeste M Lavallee 1, Andreina Bruno 2, Christopher Ma 1 3, Maitreyi Raman 1 3 4
 
63.Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
 

Clin Mol Hepatol. 2022 Nov 22. doi: 10.3350/cmh.2022.0348. Online ahead of print.

Tina Reinson 1 2, Ryan M Buchanan 3 2, Christopher D Byrne 1 2
 
64.PPARa in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?
 

Biomedicines. 2022 Nov 25;10(12):3041. doi: 10.3390/biomedicines10123041.

Claudia Theys 1, Dorien Lauwers 1, Claudina Perez-Novo 1, Wim Vanden Berghe 1
 
65.MAFLD: what 2 years of the redefinition of fatty liver disease has taught us
 

Ther Adv Endocrinol Metab. 2022 Nov 22;13:20420188221139101.doi: 10.1177/20420188221139101. eCollection 2022.

Felix Grabherr 1, Christoph Grander 1, Maria Effenberger 1, Julian Schwärzler 1, Herbert Tilg 2
 
66.Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies
 

Diagnostics (Basel). 2022 Oct 27;12(11):2608. doi: 10.3390/diagnostics12112608.

Dhaval Gosalia 1, Vlad Ratziu 2, Filip Stanicic 3, Djurdja Vukicevic 3, Vladimir Zah 3, Nadege Gunn 4, Dina Halegoua-DeMarzio 5, Tram Tran 6 7
 
67.Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies
 

Sci Rep. 2022 Nov 10;12(1):19236. doi: 10.1038/s41598-022-23905-3

 5, Danny Jonigk 5, Anna Mae Diehl 6, Manal Abdelmalek 6, Martin C Lenter 2, Steven S Pullen 3, Paolo Guarnieri 3, Birgit Stierstorfer 2 7
 
68.Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
 

Hepatology. 2022 Nov;76(5):1423-1437. doi: 10.1002/hep.32499. Epub 2022 May 2.

Zobair M Younossi 1 2 3, James M Paik 1 2, Reem Al Shabeeb 3, Pegah Golabi 1 2 3, Issah Younossi 4, Linda Henry 1 3 4
 
69.Shared Mechanisms between Cardiovascular Disease and NAFLD
 

Semin Liver Dis. 2022 Nov;42(4):455-464. doi: 10.1055/a-1930-6658.Epub 2022 Aug 25.

Daniel Q Huang 1 2 3, Michael Downes 4, Ronald M Evans 4, Joseph L Witztum 5, Christopher K Glass 6 7, Rohit Loomba 1 8
 
70.NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?
 

Semin Liver Dis. 2022 Nov;42(4):465-474. doi: 10.1055/s-0042-1757712.Epub 2022 Oct 14.

Bing Chen 1, W H Wilson Tang 2, Mario Rodriguez 3, Kathleen E Corey 4, Arun J Sanyal 5, Patrick S Kamath 6, Biykem Bozkurt 7, Hafeez Ul Hassan Virk 8, Gregg S Pressman 9, Jeffrey V Lazarus 10 11, Hashem B El-Serag 12 13, Chayakrit Krittanawong 14
 
71.Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications
 

Int J Mol Sci. 2022 Nov 1;23(21):13320. doi: 10.3390/ijms232113320.

Amedeo Lonardo 1, Alessandro Mantovani 2, Giovanni Targher 2, Gyorgy Baffy 3
 
72.Investigating microRNAs to Explain the Link between Cholesterol Metabolism and NAFLD in Humans: A Systematic Review
 

Nutrients. 2022 Nov 22;14(23):4946. doi: 10.3390/nu14234946.

Maurice C J M Konings 1, Sabine Baumgartner 1, Ronald P Mensink 1, Jogchum Plat 1
 
73.Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization
 

Radiology. 2022 Nov;305(2):265-276. doi: 10.1148/radiol.212808.Epub 2022 Sep 13.

David T Fetzer # 1, Ivan M Rosado-Mendez # 1, Michael Wang 1, Michelle L Robbin 1, Arinc Ozturk 1, Keith A Wear 1, Juvenal Ormachea 1, Timothy A Stiles 1, J Brian Fowlkes 1, Timothy J Hall 1, Anthony E Samir 1
 
74.Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis
 

Front Endocrinol (Lausanne). 2022 Nov 3;13:1032164.doi: 10.3389/fendo.2022.1032164. eCollection 2022.

Veera Houttu 1 2, Julia Bouts 1 2, Yasaman Vali 3, Joost Daams 4, Aldo Grefhorst 2, Max Nieuwdorp 1 2, Adriaan G Holleboom 1 2
 
75.Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis
 

Clin Gastroenterol Hepatol. 2022 Nov;20(11):2451-2461.e3.doi: 10.1016/j.cgh.2021.09.041. Epub 2021 Oct 7.

Anneli Andersson 1, Matt Kelly 1, Kento Imajo 2, Atsushi Nakajima 2, Jonathan A Fallowfield 3, Gideon Hirschfield 4, Michael Pavlides 5, Arun J Sanyal 6, Mazen Noureddin 7, Rajarshi Banerjee 1, Andrea Dennis 8, Stephen Harrison 9
 
76.Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-a/? agonist aleglitazar
 

PLoS One. 2022 Nov 15;17(11):e0277706.doi: 10.1371/journal.pone.0277706. eCollection 2022.

Esmée J Grobbee 1, Vivian D de Jong 2 3, Ilse C Schrieks 3, Maarten E Tushuizen 4, Adriaan G Holleboom 5, Jean-Claude Tardif 6, A Michael Lincoff 7, Gregory G Schwartz 8, Manuel Castro Cabezas 3 9 10, Diederick E Grobbee 2 3
 
77.The Synergic Effect of a Nutraceutical Supplementation Associated to a Mediterranean Hypocaloric Diet in a Population of Overweight/Obese Adults with NAFLD
 

Nutrients. 2022 Nov 10;14(22):4750. doi: 10.3390/nu14224750.

Martina Chiurazzi 1, Nunzia Cacciapuoti 1, Mariastella Di Lauro 1, Gilda Nasti 1, Margherita Ceparano 1, Elisabetta Salomone 1, Bruna Guida 1, Maria Serena Lonardo 1
 
78.Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study
 

BMC Gastroenterol. 2022 Nov 7;22(1):448. doi: 10.1186/s12876-022-02550-0.

Kathrine Aglen Seeberg 1 2 3, Dag Hofsø 4 5, Heidi Borgeraas 4, John Olav Grimnes 6, Farhat Fatima 4 7, Lars Thomas Seeberg 8, Nils Petter Kvan 6, Marius Svanevik 4 8, Jens Kristoffer Hertel 4, Jøran Hjelmesæth 4 9
 
79.Multiomics study of nonalcoholic fatty liver disease
 

Nat Genet. 2022 Nov;54(11):1652-1663. doi: 10.1038/s41588-022-01199-5. Epub 2022 Oct 24.

Gardar Sveinbjornsson # 1, Magnus O Ulfarsson # 2 3, Rosa B Thorolfsdottir 2, Benedikt A Jonsson 2, Eythor Einarsson 2, Gylfi Gunnlaugsson 2, Solvi Rognvaldsson 2, David O Arnar 2 4 5, Magnus Baldvinsson 6, Ragnar G Bjarnason 4 7, DBDS Genomic consortium; Thjodbjorg Eiriksdottir 2, Christian Erikstrup 8, Egil Ferkingstad 2, Gisli H Halldorsson 2, Hannes Helgason 2, Anna Helgadottir 2, Lotte Hindhede 8, Grimur Hjorleifsson 2, David Jones 9, Kirk U Knowlton 10, Sigrun H Lund 2, Pall Melsted 2 11, Kristjan Norland 2, Isleifur Olafsson 12, Sigurdur Olafsson 5, Gudjon R Oskarsson 2, Sisse Rye Ostrowski 13 14, Ole Birger Pedersen 14 15, Auðunn S Snaebjarnarson 2, Emil Sigurdsson 16 17, Valgerdur Steinthorsdottir 2, Michael Schwinn 13, Gudmundur Thorgeirsson 2 5, Gudmar Thorleifsson 2, Ingileif Jonsdottir 2 4, Henning Bundgaard 14 18, Lincoln Nadauld 9, Einar S Bjornsson 4 5, Ingrid C Rulifson 19, Thorunn Rafnar 2, Gudmundur L Norddahl 2, Unnur Thorsteinsdottir 2 4, Patrick Sulem 2, Daniel F Gudbjartsson 2 3 20, Hilma Holm 2, Kari Stefansson 21 22
 
80.Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease
 

Clin Gastroenterol Hepatol. 2022 Oct;20(10):2276-2286.e6.doi: 10.1016/j.cgh.2021.10.023. Epub 2021 Oct 21.

Octavi Bassegoda 1, Pol Olivas 2, Laura Turco 3, Mattias Mandorfer 4, Miquel Serra-Burriel 5, Luis Tellez 6, Wilhelmus Kwanten 7, Alexia Laroyenne 8, Oana Farcau 9, Edilmar Alvarado 10, Lucile Moga 11, Elise Vuille-Lessard 12, Jose Ignacio Fortea 13, Luis Ibañez 14, Giulia Tosetti 15, Thomas Vanwolleghem 7, Hélène Larrue 8, Diego Burgos-Santamaría 16, Horia Stefanescu 9, Rafael Paternostro 4, Annalisa Cippitelli 3, Sabela Lens 1, Salvador Augustin 17, Elba Llop 18, Wim Laleman 19, Jonel Trebicka 20, Johannes Chang 21, Helena Masnou 22, Alexander Zipprich 23, Francesca Miceli 3, Georg Semmler 4, Xavier Forns 1, Massimo Primignani 15, Rafael Bañares 14, Angela Puente 13, Annalisa Berzigotti 12, Pierre Emmanuel Rautou 11, Candid Villanueva 10, Pere Ginès 1, J C Garcia-Pagan 2, Bogdan Procopet 9, Cristophe Bureau 8, Agustin Albillos 6, Sven Francque 7, Thomas Reiberger 4, Filippo Schepis 3, Isabel Graupera 24, Virginia Hernandez-Gea 25
 
81.Gastrointestinal and liver disease in patients with schizophrenia: A narrative review
 

World J Gastroenterol. 2022 Oct 14;28(38):5515-5529.doi: 10.3748/wjg.v28.i38.5515.

Rebecca K Grant 1, William M Brindle 2, Mhairi C Donnelly 2, Pauline M McConville 3, Thomas G Stroud 3, Lorenzo Bandieri 3, John N Plevris 2
 
82.Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASH
 

Hepatol Commun. 2022 Oct 22. doi: 10.1002/hep4.2100. Online ahead of print.

Stephen A Harrison 1, Patrick R Mayo 2, Todd M Hobbs 3, Carlos Canizares 3, Erin P Foster 2, Caroline Zhao 2, Daren R Ure 2, Daniel J Trepanier 2, Jill A Greytok 3, Robert T Foster 2
 
83.Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort
 

Clin Gastroenterol Hepatol. 2022 Oct;20(10):2393-2395.e4.doi: 10.1016/j.cgh.2021.01.023. Epub 2021 Jan 21.

Miguel H Malespin 1, Alfred Sidney Barritt 4th 2, Stephanie E Watkins 3, Cheryl Schoen 3, Monica A Tincopa 4, Karen D Corbin 5, Andrea R Mospan 3, Breda Munoz 3, Huy N Trinh 6, L Michael Weiss 7, K Rajender Reddy 8, Rohit Loomba 9, Nyingi Kemmer 1, Anna S Lok 10
 
84.US Backscatter for Liver Fat Quantification: An AIUM-RSNA QIBA Pulse-Echo Quantitative Ultrasound Initiative
 

Radiology. 2022 Dec;305(3):526-537. doi: 10.1148/radiol.220606.Epub 2022 Oct 18.

Keith A Wear 1, Aiguo Han 1, Jonathan M Rubin 1, Jing Gao 1, Roberto Lavarello 1, Guy Cloutier 1, Jeffrey Bamber 1, Theresa Tuthill 1
 
85.Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality
 

Front Med (Lausanne). 2022 Oct 6;9:985803. doi: 10.3389/fmed.2022.985803.eCollection 2022.

Cheng Han Ng 1, Jieling Xiao 1, Nicholas W S Chew 1 2, Yip Han Chin 1, Kai En Chan 1, Jingxuan Quek 1, Wen Hui Lim 1, Darren Jun Hao Tan 1, Ryan Wai Keong Loke 1, Caitlyn Tan 1, Ansel Shao Pin Tang 1, Xin Lei Goh 1, Benjamin Nah 3, Nicholas Syn 1, Dan Yock Young 1 3 4, Nobuharu Tamaki 5, Daniel Q Huang 1 3 4, Mohammad Shadab Siddiqui 6, Mazen Noureddin 7, Arun Sanyal 6, Mark Muthiah 1 3 4
 
86.Dietary and nutrition considerations in caring for patients with nonalcoholic fatty liver disease: Updates for the practicing clinician
 

Nutr Clin Pract. 2022 Oct 2. doi: 10.1002/ncp.10917. Online ahead of print.

Carolyn Newberry 1, Sonal Kumar 1

 
 
87.Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers
 

Commun. 2022 Oct 11. doi: 10.1002/hep4.2073. Online ahead of print.

Scott McHenry 1, Xiaoyu Zong 2, Mengyao Shi 2 3, Cassandra D L Fritz 1, Katrina S Pedersen 4, Linda R Peterson 5, Jeffrey K Lee 6 7, Ryan C Fields 8 9, Nicholas O Davidson 1, Yin Cao 1 2 9
 
88.Approach to the Patient with Nonalcoholic Fatty Liver Disease
 

J Clin Endocrinol Metab. 2022 Oct 28;dgac624. doi: 10.1210/clinem/dgac624.Online ahead of print.

Renata Belfort-DeAguiar 1, Romina Lomonaco 2, Kenneth Cusi 2
 
89.Is Fasting Good When One Is at Risk of Liver Cancer?
 

Cancers (Basel). 2022 Oct 17;14(20):5084. doi: 10.3390/cancers14205084.

Iulia Minciuna 1 2, Laurens A van Kleef 3, Horia Stefanescu 1, Bogdan Procopet 1 2
 
90.Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
 

Nutrients. 2022 Oct 28;14(21):4556. doi: 10.3390/nu14214556.

Kiarash Riazi 1 2, Mark G Swain 1, Stephen E Congly 1, Gilaad G Kaplan 1 2 3, Abdel-Aziz Shaheen 1 2 3
 
91.Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: A Mendelian randomization study of 108,835 individuals
 

FrontImunol. 2022 Oct 24;13:1022460. doi: 10.3389/fimmu.2022.1022460. eCollection 2022.

Charlotte Näslund-Koch 1 2, Stig Egil Bojesen 2 3 4, Lise Lotte Gluud 2 5, Lone Skov 1 2, Signe Vedel-Krogh 3 4
 
92.A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease
 

Endocr Pract. 2022 Oct 20;S1530-891X(22)00648-6. doi: 10.1016/j.eprac.2022.10.007.Online ahead of print.

Clarissa Elysia Fu 1, Cheng Han Ng 2, Jie Ning Yong 1, Kai En Chan 1, Jieling Xiao 1, Benjamin Nah 3, Shirley Huey Shin Bong 4, Khin Maung Win 5, Aung Hlaing Bwa 5, Wen Hui Lim 1, Darren Jun Hao Tan 1, Rebecca Wenling Zeng 1, Nicholas Chew 6, Margaret L P Teng 3, Mohammad Shadab Siddiqui 7, Jude A Oben 8, Arun J Sanyal 7, Vincent Wai-Sun Wong 9, Mazen Noureddin 10, Mark Muthiah 11
 
93.Fecal Microbiota Transplantation in NAFLD Treatment
 

Medicina (Kaunas). 2022 Oct 30;58(11):1559. doi: 10.3390/medicina58111559.

Ludovico Abenavoli 1, Valentina Maurizi 2, Emanuele Rinninella 3 4, Jan Tack 5, Arianna Di Berardino 6, Pierangelo Santori 7, Carlo Rasetti 6 7, Anna Caterina Procopio 1, Luigi Boccuto 8, Emidio Scarpellini 5 6
 
94.Comparative effectiveness of medical treatment vs.metabolic surgery for histologically proven non-alcoholic steatohepatitis and fibrosis: a matched network meta-analysis
 

Hepatobiliary Surg Nutr. 2022 Oct;11(5):696-708. doi: 10.21037/hbsn-21-5.

Adrian T Billeter 1, Beatrice Reiners 1, Svenja E Seide 2, Pascal Probst 1 3, Eva Kalkum 3, Christian Rupp 4, Beat P Müller-Stich
 
95.Mechanisms of nonalcoholic steatohepatitis-associated cardiomyopathy: key roles for liver-heart crosstalk
 

Curr Opin Lipidol. 2022 Oct 1;33(5):295-299.doi: 10.1097/MOL.0000000000000845. Epub 2022 Aug 3.

Dolores B Njoku 1 2, Joel D Schilling 2 3, Brian N Finck 4
 
96.Porto-sinusoidal vascular disorder
 

J Hepatol. 2022 Oct;77(4):1124-1135. doi: 10.1016/j.jhep.2022.05.033.Epub 2022 Jun 9.

Andrea De Gottardi 1, Christine Sempoux 2, Annalisa Berzigotti 3
 
97.Role of non-coding RNAs on liver metabolism and NAFLD pathogenesis
 

Hum Mol Genet. 2022 Oct 20;31(R1):R4-R21. doi: 10.1093/hmg/ddac088.

Gene Qian 1, Núria Morral 1 2
 
98.Mitochondrial alterations in fatty liver diseases
 

J Hepatol. 2022 Oct 6;S0168-8278(22)03130-0. doi: 10.1016/j.jhep.2022.09.020.Online ahead of print.

Bernard Fromenty 1, Michael Roden 2
 
99.Gut-liver axis: Pathophysiological concepts and clinical implications
 

Cell Metab. 2022 Nov 1;34(11):1700-1718. doi: 10.1016/j.cmet.2022.09.017.Epub 2022 Oct 7.

Herbert Tilg 1, Timon E Adolph 2, Michael Trauner 3
 
100.GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond
 

Hepatol Commun. 2022 Oct;6(10):2613-2622. doi: 10.1002/hep4.2013.Epub 2022 May 31.

Margit Mahlapuu 1, Mara Caputo 1, Ying Xia 1, Emmelie Cansby 1
 
101.The role of oxidized lipid species in insulin resistance and NASH in children
 

Front Endocrinol (Lausanne). 2022 Oct 3;13:1019204.doi: 10.3389/fendo.2022.1019204. eCollection 2022.

Nicola Santoro 1 2 3, Ariel E Feldstein 4
 
102.The Emerging Role of Extracellular Vesicles and Autophagy Machinery in NASH-Future Horizons in NASH Management
 

Int J Mol Sci. 2022 Oct 12;23(20):12185. doi: 10.3390/ijms232012185.

Eleni-Myrto Trifylli 1 2, Anastasios G Kriebardis 1, Evangelos Koustas 2, Nikolaos Papadopoulos 2, Melanie Deutsch 3, Georgios Aloizos 2, Sotirios P Fortis 1, Effie G Papageorgiou 1, Ariadne Tsagarakis 4, Spilios Manolakopoulos 3
 
103.HCC Surveillance in NAFLD patients
 

Semin Liver Dis. 2022 Oct 10. doi: 10.1055/a-1957-8540. Online ahead of print.

George Cholankeril 1, Hashem El-Serag 1
 
104.HCC Surveillance in NAFLD patients
 

Semin Liver Dis. 2022 Oct 10. doi: 10.1055/a-1957-8540. Online ahead of print.

George Cholankeril 1, Hashem El-Serag 1
 
105.A Review of Defatting Strategies for Non-Alcoholic Fatty Liver Disease
 

Int J Mol Sci. 2022 Oct 5;23(19):11805. doi: 10.3390/ijms231911805.

Erin Nicole Young 1, Murat Dogan 1, Christine Watkins 1, Amandeep Bajwa 1, James D Eason 1, Canan Kuscu 1, Cem Kuscu 1
 
106.Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent
 

World J Surg. 2022 Oct 20. doi: 10.1007/s00268-022-06781-w. Online ahead of print.

John V Reynolds 1, Noel E Donlon 2, Jessie A Elliott 2, Brendan Moran 2, Hugo Temperley 2, Tim S Nugent 2, Maria Davern 2, Sinead King 2, Melissa Conroy 2, Joanne Lysaght 2, Narayanasamy Ravi 2, Carmel Ryan 3, Stephen Finn 3, Suzanne Norris 4, Clare L Donohoe 2
 
107.Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
 

Hepatology. 2022 Oct;76(4):1121-1134. doi: 10.1002/hep.32427. Epub 2022 Mar 17.

Ibon Martínez-Arranz 1, Chiara Bruzzone 2, Mazen Noureddin 3, Ruben Gil-Redondo 2, Itziar Mincholé 1, Maider Bizkarguenaga 2, Enara Arretxe 1, Marta Iruarrizaga-Lejarreta 1, David Fernández-Ramos 2, Fernando Lopitz-Otsoa 2, Rebeca Mayo 1, Nieves Embade 2, Elizabeth Newberry 4, Bettina Mittendorf 5, Laura Izquierdo-Sánchez 6, Vaclav Smid 7, Jorge Arnold 8, Paula Iruzubieta 9, Ylenia Pérez Castaño 10, Marcin Krawczyk 11 12, Urko M Marigorta 2, Martine C Morrison 13, Robert Kleemann 13, Antonio Martín-Duce 14, Liat Hayardeny 15, Libor Vitek 7, Radan Bruha 7, Rocío Aller de la Fuente 16, Javier Crespo 9, Manuel Romero-Gomez 17, Jesus M Banales 6 18, Marco Arrese 8 19, Kenneth Cusi 20, Elisabetta Bugianesi 21, Samuel Klein 5, Shelly C Lu 3, Quentin M Anstee 22 23, Oscar Millet 2, Nicholas O Davidson 4, Cristina Alonso 1, José M Mato 2
 
108.Review: Vascular effects of PPARs in the context of NASH
 

Aliment Pharmacol Ther. 2022 Jun 5. doi: 10.1111/apt.17046. Online ahead of print.

Sergi Guixé-Muntet 1, Louise Biquard 2, Gyongyi Szabo 3, Jean-François Dufour 4, Frank Tacke 5, Sven Francque 6 7, Pierre-Emmanuel Rautou 8, Jordi Gracia-Sancho 1 4
 
109.Treating inflammation to combat non-alcoholic fatty liver disease
 

J Endocrinol. 2022 Oct 1;JOE-22-0194. doi: 10.1530/JOE-22-0194.Online ahead of print.

Leke Wiering 1, Frank Tacke 2
 
110.A critical evaluation of the role of iron overload in fatty liver disease
 

J Gastroenterol Hepatol. 2022 Oct;37(10):1873-1883. doi: 10.1111/jgh.15971.Epub 2022 Aug 16.

Monique Fernandez 1, Julie Lokan 2, Christopher Leung 1 3, Andrew Grigg 1 4
 
111."Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV"
 

HIV Med. 2022 Sep;23(8):911-921. doi: 10.1111/hiv.13274. Epub 2022 Feb 24.

Adriana Cervo 1, Giada Sebastiani 2, Jovana Milic 3 4, Thomas Krahn 2, Sergio Mazzola 5, Salvatore Petta 6, Antonio Cascio 1, Giovanni Guaraldi 3 7, Giovanni Mazzola 1
 
112.Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis
 

J Investig Med. 2022 Oct;70(7):1452-1460. doi: 10.1136/jim-2021-002206.Epub 2022 Aug 24.

Hira Imad Cheema 1, Dirk Haselow 1, Jonathan Ankin Dranoff 2 3
 
113.Linking nutrient sensing, mitochondrial function, and PRR immune cell signaling in liver disease
 

Trends Immunol. 2022 Oct 1;S1471-4906(22)00183-1. doi: 10.1016/j.it.2022.09.002.Online ahead of print.

Claudia Kemper 1, Michael N Sack 2
 
114.NASH and hepatocellular carcinoma: immunology and immunotherapy
 

Clin Cancer Res. 2022 Sep 27;CCR-21-1258. doi: 10.1158/1078-0432.CCR-21-1258.Online ahead of print.

Matthias Pinter 1, David J Pinato 2, Pierluigi Ramadori 3, Mathias Heikenwalder 3
 
115.The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study
 

Ann Hepatol. 2022 Sep-Oct;27(5):100727. doi: 10.1016/j.aohep.2022.100727. Epub 2022 Jun 11.

Osama Hamid 1, Ahmed Eltelbany 2, Abdul Mohammed 2, Khaled Alsabbagh Alchirazi 2, Sushrut Trakroo 2, Imad Asaad 3
 
116.Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease
 

J Hepatol. 2022 Sep 5;S0168-8278(22)03059-8. doi: 10.1016/j.jhep.2022.08.028.Online ahead of print.

Emilie K Mitten 1, György Baffy 2
 
117.Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
 

Hormones (Athens). 2022 Sep;21(3):349-368. doi: 10.1007/s42000-022-00377-8.Epub 2022 Jun 4.

Stergios Kechagias 1 2, Mattias Ekstedt 3 4, Christian Simonsson 5 6, Patrik Nasr 3 4
 
118. Exercise during weight loss improves hepatic mitophagy
 

Sports Med Health Sci. 2022 Apr 12;4(3):183-189. doi: 10.1016/j.smhs.2022.04.003.eCollection 2022 Sep.

Megan E Rosa-Caldwell 1 2, Kaylee E Poole 3, Andrew Seija 3, Matthew P Harris 3, Nicholas P Greene 1, Joshua S Wooten 3
 
119.Therapies for non-alcoholic fatty liver disease: A 2022 update
 

World J Hepatol. 2022 Sep 27;14(9):1718-1729. doi: 10.4254/wjh.v14.i9.1718.

Katie Shen 1, Achintya D Singh 2, Jamak Modaresi Esfeh 3, Jamile Wakim-Fleming 3
 
120.Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis
 

World J Gastroenterol. 2022 Sep 21;28(35):5129-5140.doi: 10.3748/wjg.v28.i35.5129.

Jaspreet Suri 1, Sebastian Borja 2, Joseph K Lim 3
 
121.Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis
 

Nutr Metab Cardiovasc Dis. 2022 Oct;32(10):2279-2288.doi: 10.1016/j.numecd.2022.07.001. Epub 2022 Jul 16.

Grazia Pennisi 1, Ciro Celsa 1, Marco Enea 2, Marco Vaccaro 2, Vito Di Marco 1, Carlo Ciccioli 1, Giuseppe Infantino 1, Claudia La Mantia 1, Stefanie Parisi 1, Federica Vernuccio 3, Antonio Craxì 1, Calogero Cammà 1, Salvatore Petta 4
 
122.Immune-metabolic interactions in homeostasis and the progression to NASH
 

Trends Endocrinol Metab. 2022 Oct;33(10):690-709. doi: 10.1016/j.tem.2022.07.001.Epub 2022 Aug 10.

Joanne A Hoogerland 1, Bart Staels 1, David Dombrowicz 2
 
123.The Impact of Bariatric-Surgery-Induced Weight Loss on Patients Undergoing Liver Transplant: A Focus on Metabolism, Pathophysiological Changes, and Outcome in Obese Patients Suffering NAFLD-Related Cirrhosis
 

J Clin Med. 2022 Sep 8;11(18):5293. doi: 10.3390/jcm11185293.

Gerardo Sarno 1, Luigi Schiavo 2 3, Pietro Calabrese 2 3, Ludwig Álvarez Córdova 4, Evelyn Frias-Toral 5 6, Gabriela Cucalón 7, Eloisa Garcia-Velasquez 8, Vanessa Fuchs-Tarlovsky 9, Vincenzo Pilone 2 3
 
124.Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort
 

Gut. 2022 Sep;71(9):1867-1875. doi: 10.1136/gutjnl-2021-325724. Epub 2021 Sep 6.

Tracey G Simon 1 2, Bjorn Roelstraete 3, Hannes Hagström 4 5 6, Johan Sundström 7 8 9, Jonas F Ludvigsson 10 11 12 13
 
125.Combination Treatment with Hydroxytyrosol and Vitamin E Improves NAFLD-Related Fibrosis
 

Nutrients. 2022 Sep 14;14(18):3791.

Nadia Panera 1, Maria Rita Braghini 1, Annalisa Crudele 1, Antonella Smeriglio 2, Marzia Bianchi 1, Angelo Giuseppe Condorelli 3, Rebecca Nobili 3, Libenzio Adrian Conti 4, Cristiano De Stefanis 4, Gessica Lioci 5, Fabio Gurrado 5, Donatella Comparcola 6, Antonella Mosca 6, Maria Rita Sartorelli 6, Vittorio Scoppola 1, Gianluca Svegliati-Baroni 7 8, Domenico Trombetta 2, Anna Alisi 1
 
126.Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention
 

Cells. 2022 Sep 10;11(18):2827. doi: 10.3390/cells11182827.

Lucrezia Irene Maria Campagnoli 1, Nicoletta Marchesi 1, Mariapia Vairetti 2, Alessia Pascale 1, Andrea Ferrigno 2, Annalisa Barbieri 1
 
127.Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes
 

Diabetes Metab. 2022 Sep;48(5):101363. doi: 10.1016/j.diabet.2022.101363. Epub 2022 Jun 24.

Erminia Lembo 1, Maria Francesca Russo 1, Ornella Verrastro 1, Danila Anello 1, Giulia Angelini 1, Amerigo Iaconelli 1, Caterina Guidone 1, Gianluigi Stefanizzi 1, Luigi Ciccoritti 1, Francesco Greco 1, Luca Sessa 1, Laura Riccardi 1, Maurizio Pompili 1, Marco Raffaelli 1, Fabio Maria Vecchio 1, Stefan R Bornstein 2, Geltrude Mingrone 3, Amalia Gastaldelli 4, Esmeralda Capristo 1
 
128.Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist
 

J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt A):2616-2627.doi: 10.1053/j.jvca.2021.07.020. Epub 2021 Jul 15.

Sonal Sharma 1, Jonathan G Stine 2, Thomas Verbeek 3, Dmitri Bezinover 4
 
129.Current treatment of non-alcoholic fatty liver disease
 

J Intern Med. 2022 Aug;292(2):190-204. doi: 10.1111/joim.13531. Epub 2022 Jul 7.

Rafael Paternostro 1, Michael Trauner 1
 
130.Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
 

Int J Mol Sci. 2022 Jul 27;23(15):8307. doi: 10.3390/ijms23158307.

Roberta Forlano 1, Mathuri Sivakumar 2, Benjamin H Mullish 1, Pinelopi Manousou 1
 
131.Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers
 

Mayo Clin Proc. 2022 Sep;97(9):1700-1716. doi: 10.1016/j.mayocp.2022.04.005.

Rita Basu 1, Mazen Noureddin 2, Jeanne M Clark 3
 
132.Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis
 

Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Nov;1867(11):159209.doi: 10.1016/j.bbalip.2022.159209. Epub 2022 Aug 4.

Curtis C Hughey 1, Patrycja Puchalska 2, Peter A Crawford 3
 
133.Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world
 

Aliment Pharmacol Ther. 2022 Sep;56(6):942-956. doi: 10.1111/apt.17158.Epub 2022 Jul 26.

Linda Henry 1, James Paik 2, Zobair M Younossi 3
 
134.Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
 

Curr Obes Rep. 2022 Sep;11(3):166-179. doi: 10.1007/s13679-022-00474-0.Epub 2022 May 2.

Stergios A Polyzos 1, Dimitrios G Goulis 2, Olga Giouleme 3, Georgios S Germanidis 4, Antonis Goulas 5
 
135.Evaluation of liver transplant candidates with non-alcoholic steatohepatitis
 

Transl Gastroenterol Hepatol. 2022 Jul 25;7:24. doi: 10.21037/tgh.2020.03.04.eCollection 2022.

James Philip G Esteban 1 2, Amon Asgharpour 2
 
136.Evidence-based management of patients with nonalcoholic fatty liver disease
 

JAAPA. 2022 Aug 1;35(8):20-24. doi: 10.1097/01.JAA.0000840492.53680.59.

Minal Patel 1
 
137.Role of Ultrasound Methods for the Assessment of NAFLD
 

J Clin Med. 2022 Aug 5;11(15):4581. doi: 10.3390/jcm11154581.

Golo Petzold 1
 
138.Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification
 

Atherosclerosis. 2022 Sep;357:51-59. doi: 10.1016/j.atherosclerosis.2022.08.011.Epub 2022 Aug 20.

Francesco Baratta 1, Laura D'Erasmo 2, Simone Bini 2, Daniele Pastori 1, Francesco Angelico 3, Maria Del Ben 1, Marcello Arca 2, Alessia Di Costanzo 4
 
139.Liver, NAFLD and COVID-19
 

Horm Metab Res. 2022 Aug;54(8):522-531. doi: 10.1055/a-1834-9008.Epub 2022 Apr 25.

Carlotta Hoffmann 1, Philipp A Gerber 2, Claudia Cavelti-Weder 2, Louisa Licht 1, Reham Kotb 3, Rania Al Dweik 4, Michele Cherfane 3, Stefan R Bornstein 1, Nikolaos Perakakis 1 5 6
 
140.Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies
 

Clin Gastroenterol Hepatol. 2022 Aug 4;S1542-3565(22)00733-9.doi: 10.1016/j.cgh.2022.07.033. Online ahead of print.

Phuc Le 1, Julia Yang Payne 2, Lu Zhang 3, Abhishek Deshpande 4, Michael B Rothberg 4, Naim Alkhouri 5, William Herman 6, Adrian V Hernandez 7, Mary Schleicher 8, Wen Ye 9, Srinivasan Dasarathy 10
 
141.Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD
 

Semin Liver Dis. 2022 Aug;42(3):233-249. doi: 10.1055/s-0042-1755316.Epub 2022 Aug 24.

Raquel Carvalho-Gontijo # 1 2, Cuijuan Han # 1 2, Lei Zhang 1 2, Vivian Zhang 1 2, Mojgan Hosseini 3, Kristin Mekeel 2, Bernd Schnabl 1, Rohit Loomba 1, Michael Karin 4, David A Brenner 1, Tatiana Kisseleva 2
 
142.Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
 

Clin Gastroenterol Hepatol. 2022 Sep;20(9):2050-2058.e12.doi: 10.1016/j.cgh.2021.07.020. Epub 2021 Jul 15.

Zobair M Younossi 1, Maria Stepanova 2, Fatema Nader 2, Rohit Loomba 3, Quentin M Anstee 4, Vlad Ratziu 5, Stephen Harrison 6, Arun J Sanyal 7, Jörn M Schattenberg 8, A Sidney Barritt 9, Mazen Noureddin 10, Martin Bonacci 11, Gail Cawkwell 11, Bruce Wong 11, Mary Rinella 12, RandomizEd Global Phase 3 Study to Evaluate the Impact on NASH with FibRosis of Obeticholic Acid TreatmEnt (REGENERATE) Study Investigators
 
143.Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
 

J Hepatol. 2022 Sep;77(3):607-618.doi: 10.1016/j.jhep.2022.04.003.Epub 2022 Apr 16.

Naim Alkhouri 1, Robert Herring 2, Heidi Kabler 3, Zeid Kayali 4, Tarek Hassanein 5, Anita Kohli 6, Ryan S Huss 7, Yanni Zhu 7, Andrew N Billin 7, Lars Holm Damgaard 8, Kristine Buchholtz 8, Mette Skalshøi Kjær 8, Clare Balendran 8, Robert P Myers 7, Rohit Loomba 9, Mazen Noureddin 10
 
144.The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes
 

JHEP Rep. 2022 Jun 15;4(9):100525. doi: 10.1016/j.jhepr.2022.100525. eCollection 2022 Sep.

Zobair Younossi 1 2, Priya Aggarwal 3, Ichhya Shrestha 4, João Fernandes 4, Pierre Johansen 5, Margarida Augusto 6, Sunita Nair 7
 
145.Statins' efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis
 

Clin Nutr. 2022 Aug 8;41(10):2195-2206. doi: 10.1016/j.clnu.2022.08.001. Online ahead of print.

Chrysoula Boutari 1, Panagiotis D Pappas 2, Dimitrios Anastasilakis 3, Christos S Mantzoros 4
 
146.Adherence to Mediterranean Diet and NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study
 

Nutrients. 2022 Aug 3;14(15):3186. doi: 10.3390/nu14153186.

Sofía Montemayor 1 2, Catalina M Mascaró 1 2, Lucía Ugarriza 1 2 3, Miguel Casares 4, Isabel Llompart 1 2 5, Itziar Abete 6 7, María Ángeles Zulet 6 7, J Alfredo Martínez 7 8, Josep A Tur 1 2 6, Cristina Bouzas 1 2 6
 
147.Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis
 

Clin Gastroenterol Hepatol. 2022 Jul;20(7):1561-1569.e4. doi: 10.1016/j.cgh.2021.06.012.Epub 2021 Jun 10.

Haley Schoenberger 1, Nicolas Chong 1, David T Fetzer 2, Nicole E Rich 1, Takeshi Yokoo 2, Gaurav Khatri 2, Jocelyn Olivares 3, Neehar D Parikh 4, Adam C Yopp 5, Jorge A Marrero 3, Amit G Singal 6
 
148.Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients
 

J Lipid Res. 2022 Jul 11;63(9):100250. doi: 10.1016/j.jlr.2022.100250. Online ahead of print.

Eric J Lawitz 1, Kelvin W Li 2, Edna Nyangau 2, Tyler John Field 2, Jen-Chieh Chuang 3, Andrew Billin 3, Lulu Wang 3, Ya Wang 3, Ryan S Huss 3, Chuhan Chung 3, G Mani Subramanian 3, Robert P Myers 3, Marc K Hellerstein 4
 
149.The role of bariatric surgery in liver transplantation: timing and type
 

Langenbecks Arch Surg. 2022 Jul 19. doi: 10.1007/s00423-022-02606-5. Online ahead of print.

Danial Safavi 1, Ben Creavin 2, Tom K Gallagher 3 4, Michael E Kelly 3 5
 
150.Early biochemical observations point to nutritional strategies to manage non-alcoholic fatty liver disease
 

Clin Sci (Lond). 2022 Jul 15;136(13):1019-1023. doi: 10.1042/CS20220380.

Philip C Calder 1 2
 
151.Nonalcoholic Fatty Liver Disease and Risk of Dementia: A Population-Based Cohort Study
 

Neurology. 2022 Jul 13;10.1212/WNL.0000000000200853.doi: 10.1212/WNL.0000000000200853. Online ahead of print.

Ying Shang 1, Linnea Widman 2, Hannes Hagström 3 4 5
 
152.Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design
 

J Hepatol. 2022 Jul 14;S0168-8278(22)02936-1. doi: 10.1016/j.jhep.2022.07.004.Online ahead of print.

Alina M Allen 1, Terry M Therneau 2, Omar Tarek Ahmed 3, Tolga Gidener 4, Kristin C Mara 5, Joseph J Larson 6, Rachel E Canning 7, Joanne T Benson 8, Patrick S Kamath 9
 
153.NASH Presence is Associated with a Lower Weight Loss One and 2 Years After Bariatric Surgery in Women with Severe Obesity
 

Obes Surg. 2022 Jul 6. doi: 10.1007/s11695-022-06175-w. Online ahead of print.

Fàtima Sabench # 1 2, Laia Bertran # 2, Margarita Vives 1, Marta París 1, Carmen Aguilar 2, Salomé Martínez 2, Jessica Binetti 2 3, Monica Real 3, Alja Alibalic 3, Cristóbal Richart 2, Daniel Del Castillo 1 2, Teresa Auguet 4 5
 
154.Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey
 

BMC Gastroenterol. 2022 Jul 10;22(1):335. doi: 10.1186/s12876-022-02410-x.

Mary Rinella 1, Donna R Cryer 2, Amy Articolo 3, Travis Fisher 3, Jennifer Schneider 3, Karl Nadolsky 4
 
155.The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting
 

Clin Gastroenterol Hepatol. 2022 Jul 8;S1542-3565(22)00603-6.doi: 10.1016/j.cgh.2022.05.046. Online ahead of print.

Aaron P Thrift 1, Theresa H Nguyen 2, Codey Pham 3, Maya Balakrishnan 4, Fasiha Kanwal 2, Rohit Loomba 5, Hao T Duong 6, David Ramsey 7, Hashem B El-Serag 2
 
156.Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD
 

Radiology. 2022 Jul;304(1):75-82. doi: 10.1148/radiol.211131. Epub 2022 Mar 29.

Jinho Jung 1, Aiguo Han 1, Egbert Madamba 1, Ricki Bettencourt 1, Rohan R Loomba 1, Andrew S Boehringer 1, Michael P Andre 1, John W Erdman Jr 1, William D O'Brien Jr 1, Kathryn J Fowler 1, Claude B Sirlin 1, Rohit Loomba 1
 
157.AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
 

Gastroenterology. 2022 Sep;163(3):764-774.e1.doi: 10.1053/j.gastro.2022.06.023. Epub 2022 Jul 14.

Michelle T Long 1, Mazen Noureddin 2, Joseph K Lim 3
 
158.Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLD
 

Semin Liver Dis. 2022 Aug;42(3):313-326. doi: 10.1055/s-0042-1751081. Epub 2022 Jul 14.

Laurent Castera 1 2, Jérôme Boursier 3 4
 
159.Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning
 

Hepatol Commun. 2022 Jul;6(7):1537-1548. doi: 10.1002/hep4.1935. Epub 2022 Apr 1.

Mazen Noureddin 1, Fady Ntanios 2, Deepa Malhotra 2, Katherine Hoover 2, Birol Emir 2, Euan McLeod 3, Naim Alkhouri 4
 
160.Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation
 

J Clin Pathol. 2022 Jul;75(7):443-451. doi: 10.1136/jclinpath-2022-208246.Epub 2022 Apr 12.

Chiyun Wang 1, Anita K Pai 2, Juan Putra 3
 
161.Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver disease
 

Curr Opin Clin Nutr Metab Care. 2022 Jul 1;25(4):248-255.doi: 10.1097/MCO.0000000000000845.

Philip C Calder 1 2
 
162.Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
 

Nat Rev Gastroenterol Hepatol. 2022 Jul;19(7):432-450.doi: 10.1038/s41575-021-00566-7. Epub 2022 Feb 14.

Claudia D Fuchs 1, Michael Trauner 2
 
163.Differences in NAFLD/NASH Management by Provider Specialty: Opportunities for Optimizing Multidisciplinary Care
 

J Multidiscip Healthc. 2022 Jul 19;15:1533-1545. doi: 10.2147/JMDH.S367607. eCollection 2022.

Michael K Porayko 1, Amy Articolo 2, Wendy Cerenzia 3, Brandon Coleman 3, Daxa Patel 2, Sylvie Stacy 3
 
164.Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis
 

J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1057-1068. doi: 10.1016/j.jceh.2022.01.011.Epub 2022 Feb 1.

Alexander J Kovalic 1 2
 
165.Combination Therapies for Nonalcoholic Fatty Liver Disease
 

J Pers Med. 2022 Jul 18;12(7):1166. doi: 10.3390/jpm12071166.

Evangelia S Makri 1, Eleftheria Makri 1, Stergios A Polyzos 1
 
166.Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation
 

Nat Rev Endocrinol. 2022 Jul 15. doi: 10.1038/s41574-022-00711-5.Online ahead of print.

Amedeo Lonardo 1, Alessandro Mantovani 2, Salvatore Petta 3, Amedeo Carraro 4, Christopher D Byrne 5 6, Giovanni Targher 7
 
167.Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives
 

Aliment Pharmacol Ther. 2022 Aug;56(4):570-579. doi: 10.1111/apt.17121.Epub 2022 Jul 6.

Cheng Han Ng 1, Wen Hui Lim 1, Yip Han Chin 1, Jie Ning Yong 1, Rebecca Wenling Zeng 1, Kai En Chan 1, Darren Jun Hao Tan 1, Clarissa Elysia Fu 1, Ansel Shao Pin Tang 1, Lay Hoon Goh 2, Kamala Devi 3, Nicholas W S Chew 1 4, Lung-Yi Loey Mak 5, Nobuharu Tamaki 6 7, Daniel Q Huang 1 8 9, Mazen Noureddin 10, Mohammad Shadab Siddiqui 11, Rohit Loomba 6, Arun J Sanyal 11, Mark Muthiah 1 8 9
 
168.The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis
 

Clin Nutr. 2022 Jul 2;41(9):1913-1931. doi: 10.1016/j.clnu.2022.06.037. Online ahead of print.

Laura Haigh 1, Colette Kirk 2, Khalil El Gendy 3, Jennifer Gallacher 4, Linda Errington 5, John C Mathers 3, Quentin M Anstee 4
 
169.Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis
 

EClinicalMedicine. 2022 Jul 1;50:101534. doi: 10.1016/j.eclinm.2022.101534.eCollection 2022 Aug.

Adam Minich 1, Fakhar Ali Qazi Arisar 2 3 4, Noor-Ul Saba Shaikh 2, Leanne Herman 1, Amirhossein Azhie 2, Ani Orchanian-Cheff 5, Keyur Patel 3 6, Sareh Keshavarzi 7 8, Mamatha Bhat 2 3
 
170.Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
 

Nat Med. 2022 Jul;28(7):1432-1438. doi: 10.1038/s41591-022-01861-9.Epub 2022 Jun 20

Stephen A Harrison 1, Federico Perez Manghi 2, William B Smith 3, Diana Alpenidze 4, Diego Aizenberg 5, Naomi Klarenbeek 6, Chi-Yi Chen 7, Eli Zuckerman 8, Eric Ravussin 9, Phunchai Charatcharoenwitthaya 10, Pin-Nan Cheng 11, Helena Katchman 12, Samuel Klein 13, Ziv Ben-Ari 14, Anisha E Mendonza 15, Yiming Zhang 16, Miljen Martic 17, Shenglin Ma 15, Sheena Kao 18, Sandra Tanner 17, Alok Pachori 15, Michael K Badman 15, YanLing He 15, Chinweike Ukomadu 15, Eric Sicard 19
 
171.The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
 

Lancet Gastroenterol Hepatol. 2022 Jul 4;S2468-1253(22)00165-0.doi: 10.1016/S2468-1253(22)00165-0. Online ahead of print.

Kiarash Riazi 1, Hassan Azhari 2, Jacob H Charette 2, Fox E Underwood 3, James A King 3, Elnaz Ehteshami Afshar 1, Mark G Swain 2, Stephen E Congly 4, Gilaad G Kaplan 3, Abdel-Aziz Shaheen 5
 
172.Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study
 

Eur J Epidemiol. 2022 Jul;37(7):723-733. doi: 10.1007/s10654-022-00868-3.Epub 2022 Apr 30.

Shuai Yuan 1, Jie Chen 2 3, Xue Li 4 5, Rongrong Fan 6, Benoit Arsenault 7 8, Dipender Gill 9 10 11 12, Edward L Giovannucci 13 14, Ju-Sheng Zheng # 15, Susanna C Larsson # 16 17
 
173.Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials
 

Nutrients. 2022 Jul 12;14(14):2846. doi: 10.3390/nu14142846.

Danielle Lee 1 2, Laura Chiavaroli 1 2, Sabrina Ayoub-Charette 1 2, Tauseef A Khan 1 2, Andreea Zurbau 1 2 3, Fei Au-Yeung 1 2 3, Annette Cheung 1 2, Qi Liu 1 2, Xinye Qi 1 2, Amna Ahmed 1 2, Vivian L Choo 1 2 4, Sonia Blanco Mejia 1 2, Vasanti S Malik 1 5, Ahmed El-Sohemy 1, Russell J de Souza 1 2 6 7, Thomas M S Wolever 1 3 8, Lawrence A Leiter 1 2 8 9 10, Cyril W C Kendall 1 2 11, David J A Jenkins 1 2 8 9 10, John L Sievenpiper 1 2 8 9 10
 
174.The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis
 

Kans J Med. 2022 Jul 21;15:241-246. doi: 10.17161/kjm.vol15.16522. eCollection 2022.

Umar Hayat 1, Muhammad Zubair Ashfaq 2, Luke Johnson 1, Ryan Ford 1, Chelsea Wuthnow 1, Kevin Kadado 1, Katia El Jurdi 1, Hayrettin Okut 3, William Ransom Kilgore 1 4, Maha Assi 1 5, Ali A Siddiqui 6
 
175.Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals
 

Endocr Pract. 2022 Jul;28(7):667-672. doi: 10.1016/j.eprac.2022.03.016.Epub 2022 Mar 29.

Jingxuan Quek 1, Cheng Han Ng 2, Ansel Shao Pin Tang 1, Nicholas Chew 3, Mark Chan 3, Chin Meng Khoo 4, Chen Poh Wei 1, Yip Han Chin 1, Phoebe Tay 1, Grace Lim 5, Darren Jun Hao Tan 1, Wen Hui Lim 1, Kai En Chan 1, Margaret Teng 6, Eunice Tan 7, Nobuharu Tamaki 8, Daniel Q Huang 7, Mohammad Shadab Siddiqui 9, Dan Yock Young 6, Mazen Noureddin 10, Mark D Muthiah 11
 
176.Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment
 

Liver Int. 2022 Aug;42(8):1772-1782. doi: 10.1111/liv.15324. Epub 2022 Jun 9.

Patrice Lazure 1, Jeremy W Tomlinson 2, Kris V Kowdley 3, Paolo Magni 4 5 6, Raul D Santos 6 7 8, Ginny Jacobs 9, Suzanne Murray 1
 
177.The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review
 

Pharmacoeconomics. 2022 Aug;40(8):751-776. doi: 10.1007/s40273-022-01140-y.Epub 2022 Jul 5.

Michal Witkowski 1, Søren Ilsøe Moreno 2, João Fernandes 2, Pierre Johansen 3, Margarida Augusto 4, Sunita Nair 5
 
178.Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis
 

BMC Gastroenterol. 2022 Jun 30;22(1):323. doi: 10.1186/s12876-022-02401-y.

Kushala W M Abeysekera 1 2, James G Orr 3, Fiona H Gordon 3, Laura D Howe 4 5, Julian Hamilton-Shield 6, Jon Heron 4, Matthew Hickman 4 5
 
179.The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis
 

Inflamm Bowel Dis. 2022 Jun 3;28(6):878-887. doi: 10.1093/ibd/izab199.

Shaya Noorian 1 2, Yejoo Jeon 1 2, Minh T Nguyen 2, Jenny Sauk 1 2, Berkeley N Limketkai 1 2
 
180.A minority of somatically mutated genes in pre-existing fatty liver disease have prognostic importance in the development of NAFLD
 

Liver Int. 2022 Aug;42(8):1823-1835. doi: 10.1111/liv.15283. Epub 2022 May 11.

Jake P Mann 1 2, Matthew Hoare 2 3
 
181.A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma
 

FASEB J. 2022 Jul;36(7):e22372. doi: 10.1096/fj.202200346R.

Christopher D Green 1, Cynthia Weigel 1, Ryan D R Brown 1, Pierre Bedossa 2 3, Mikhail Dozmorov 4, Arun J Sanyal 2, Sarah Spiegel 1
 
182.Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis
 

Obes Surg. 2022 Aug;32(8):2495-2503. doi: 10.1007/s11695-022-06150-5. Epub 2022 Jun 17.

Thomas Karlas # 1, David Petroff # 2 3, Jürgen Feisthammel 4, Sebastian Beer 4, Matthias Blüher 3 5, Tatjana Schütz 3, Ralf Lichtinghagen 6, Albrecht Hoffmeister 4, Johannes Wiegand 7
 
183.American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)
 

Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

Kenneth Cusi 1, Scott Isaacs 2, Diana Barb 3, Rita Basu 4, Sonia Caprio 5, W Timothy Garvey 6, Sangeeta Kashyap 7, Jeffrey I Mechanick 8, Marialena Mouzaki 9, Karl Nadolsky 10, Mary E Rinella 11, Miriam B Vos 12, Zobair Younossi 13
 
184.Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
 

Int J Mol Sci. 2022 Jun 23;23(13):6996. doi: 10.3390/ijms23136996.

Pallavi Subramanian 1, Jochen Hampe 2, Frank Tacke 3, Triantafyllos Chavakis 1 4 5
 
185.Frailty in metabolic syndrome, focusing on nonalcoholic fatty liver disease
 

Ann Gastroenterol. 2022 May-Jun;35(3):234-242. doi: 10.20524/aog.2022.0705.Epub 2022 Mar 25.

Nikolaos D Karakousis 1 2, Lampros Chrysavgis 2, Antonios Chatzigeorgiou 2 3, George Papatheodoridis 1, Evangelos Cholongitas 4
 
186.Mediterranean Diet: The Beneficial Effects of Lycopene in Non-Alcoholic Fatty Liver Disease
 

J Clin Med. 2022 Jun 16;11(12):3477. doi: 10.3390/jcm11123477.

Ludovico Abenavoli 1, Anna Caterina Procopio 1, Maria Rosaria Paravati 1, Giosuè Costa 1 2 3, Nataša Milic 4, Stefano Alcaro 1 2 3, Francesco Luzza 1
 
187.Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease
 

Curr Atheroscler Rep. 2022 Jul;24(7):515-532. doi: 10.1007/s11883-022-01027-5.Epub 2022 May 4.

Nicholas W S Chew 1, Cheng Han Ng 2, Mark Dhinesh Muthiah 3, Arun J Sanyal 4
 
188.Understanding the cellular interactome of non-alcoholic fatty liver disease
 

JHEP Rep. 2022 Jun 15;4(8):100524. doi: 10.1016/j.jhepr.2022.100524.eCollection 2022 Aug.

Sebastian J Wallace 1, Frank Tacke 2, Robert F Schwabe 2 3 4 5, Neil C Henderson 1 6
 
189.Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques
 

Obes Rev. 2022 Jun 12. doi: 10.1111/obr.13481. Online ahead of print.

Willy Theel 1 2, Bianca M Boxma-de Klerk 3, Femme Dirksmeier-Harinck 4, Elisabeth F C van Rossum 2 5, Danny A Kanhai 6, Jan Apers 7, Bas M van Dalen 8, Robert J de Knegt 9, Anthony G Holleboom 10, Maarten E Tushuizen 11, Diederick E Grobbee 12 13, Janneke Wiebolt 1 2, Manuel Castro Cabezas 1 5 13
 
190.The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population-A Review
 

Life (Basel). 2022 Jun 5;12(6):839. doi: 10.3390/life12060839.

Thomas Pixner 1 2, Nathalie Stummer 2 3, Anna Maria Schneider 2 3, Andreas Lukas 1 2, Karin Gramlinger 1, Valérie Julian 4, David Thivel 5, Katharina Mörwald 2 3, Katharina Maruszczak 2 3, Harald Mangge 6, Julian Gomahr 2 3, Daniel Weghuber 2 3, Dieter Furthner 1 2
 
191.The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications
 

J Clin Med. 2022 Jun 24;11(13):3649. doi: 10.3390/jcm11133649.

Rossella Palma 1, Annamaria Pronio 1, Mario Romeo 2, Flavia Scognamiglio 2, Lorenzo Ventriglia 2, Vittorio Maria Ormando 3, Antonietta Lamazza 4, Stefano Pontone 5, Alessandro Federico 2, Marcello Dallio 2
 
192.One size does not fit all; practical, personal tailoring of the diet to NAFLD patients
 

Liver Int. 2022 Jun 8. doi: 10.1111/liv.15335. Online ahead of print.

Shira Zelber-Sagi 1 2, Laura Sol Grinshpan 1 2, Dana Ivancovsky-Wajcman 1 2, Ariela Goldenshluger 3, Yftach Gepner 3
 
193.Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
 

Cureus. 2022 May 30;14(5):e25495. doi: 10.7759/cureus.25495.eCollection 2022 May.

Gashaw Hassen 1 2 3 4, Abhishek Singh 5, Gizeshwork Belete 6, Nidhi Jain 7 8 9, Ivonne De la Hoz 10, Genesis P Camacho-Leon 11 12, Nitsuh K Dargie 13, Keila G Carrera 14, Tadesse Alemu 15, Sharan Jhaveri 16, Nebiyou Solomon 15
 
194.Growth hormone deficiency and NAFLD: An overlooked and underrecognized link
 

Hepatol Commun. 2022 Jun 28. doi: 10.1002/hep4.1953. Online ahead of print.

Iliana Doycheva 1, Dana Erickson 2, Kymberly D Watt 3
 
195.Bariatric surgery and non-alcoholic fatty liver disease
 

Med Clin (Barc). 2022 Jun 10;158(11):550-555. doi: 10.1016/j.medcli.2021.12.003.Epub 2022 Feb 2.

Helena Julià 1, David Benaiges 2, Juan Pedro-Botet 3
 
196.NAFLD: Mechanisms, Treatments, and Biomarkers
 

Biomolecules. 2022 Jun 13;12(6):824. doi: 10.3390/biom12060824.

Fatiha Nassir 1
 
197.COVID-19 and liver diseases, what we know so far
 

World J Clin Cases. 2022 May 6;10(13):3969-3980.doi: 10.12998/wjcc.v10.i13.3969.

Mohamed Elnaggar 1, Ahmed Abomhya 2, Ismail Elkhattib 3, Nabila Dawoud 4, Rajkumar Doshi 5
 
198.When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD
 

J Clin Med. 2022 Jun 8;11(12):3286. doi: 10.3390/jcm11123286.

Alba Rojano-Toimil 1 2, Jesús Rivera-Esteban 2 3 4, Ramiro Manzano-Nuñez 2 4, Juan Bañares 2 4, David Martinez Selva 2 5, Pablo Gabriel-Medina 6 7, Roser Ferrer 6, Juan M Pericàs 2 4 8, Andreea Ciudin 1 2 3 5
 
199.Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants
 

Gastroenterology. 2022 Jul 1;S0016-5085(22)00735-1. doi: 10.1053/j.gastro.2022.06.073.Online ahead of print.

Veeral Ajmera 1, Beom Kyung Kim 2, Kun Yang 3, Abdul M Majzoub 4, Tarek Nayfeh 5, Nobuharu Tamaki 6, Namiki Izumi 7, Atsushi Nakajima 8, Ramazan Idilman 9, Mesut Gumussoy 9, Digdem Kuru Oz 10, Ayse Erden 10, Natalie E Quach 3, Xin Tu 3, Xinlian Zhang 3, Mazen Noureddin 11, Alina M Allen 12, Rohit Loomba 13
 
200.Effect of Dietary and Lifestyle Interventions on the Amelioration of NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study
 

Nutrients. 2022 May 26;14(11):2223. doi: 10.3390/nu14112223.

Sofía Montemayor 1 2, Cristina Bouzas 1 2 3, Catalina M Mascaró 1 2, Miguel Casares 4, Isabel Llompart 1 2 5, Itziar Abete 3 6, Escarlata Angullo-Martinez 1 2 7, María Ángeles Zulet 3 6, J Alfredo Martínez 6 8, Josep A Tur 1 2 3
 
201.Premenopausal Syndrome and NAFLD: A New Approach Based on Gender Medicine
 

Biomedicines. 2022 May 20;10(5):1184. doi: 10.3390/biomedicines10051184.

Livianna Carrieri 1, Alberto Ruben Osella 2, Fausto Ciccacci 3, Gianluigi Giannelli 4, Maria Principia Scavo 1
 
202.Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis
 

World J Hepatol. 2022 May 27;14(5):1025-1037. doi: 10.4254/wjh.v14.i5.1025.

Nicole Cianci 1, Mohsan Subhani 2, Trevor Hill 2, Amardeep Khanna 2, Dong Zheng 3, Abhishek Sheth 2, Colin Crooks 2, Guruprasad P Aithal 2
 
203.Risk stratification of adolescents for the screening of non-alcoholic fatty liver disease
 

Pediatr Obes. 2022 May 2;e12924. doi: 10.1111/ijpo.12924. Online ahead of print.

Gary A Abrams 1, Deanna Ware 2 3, Margaret M Byrne 4, Eric M Hecht 3 5 6
 
204.Reduction of De Novo Lipogenesis Mediates Beneficial Effects of Isoenergetic Diets on Fatty Liver: Mechanistic Insights from the MEDEA Randomized Clinical Trial
 

Nutrients. 2022 May 23;14(10):2178. doi: 10.3390/nu14102178.

Giuseppina Costabile 1 2, Giuseppe Della Pepa 1, Dominic Salamone 1, Delia Luongo 3, Daniele Naviglio 4, Valentina Brancato 5, Carlo Cavaliere 5, Marco Salvatore 5, Paola Cipriano 1, Marilena Vitale 1, Alessandra Corrado 1, Angela Albarosa Rivellese 1 2, Giovanni Annuzzi 1 2, Lutgarda Bozzetto 1 2
 
205.Lipid balance must be just right to prevent development of severe liver damage
 

J Clin Invest. 2022 Jun 1;132(11):e160326. doi: 10.1172/JCI160326.

Timothy F Osborne 1, Peter J Espenshade 2
 
206.Alcohol Consumption: Medical Implications, the Liver and Beyond
 

Alcohol Alcohol. 2022 May 10;57(3):283-291. doi: 10.1093/alcalc/agac013.

Víctor Meza 1, Jorge Arnold 2, Luis Antonio Díaz 2, María Ayala Valverde 3, Francisco Idalsoaga 2, Gustavo Ayares 2, Deepika Devuni 4, Juan Pablo Arab 2
 
207.Dietary Vitamin E Intake Is Associated With a Reduced Risk of Developing Digestive Diseases and Nonalcoholic Fatty Liver Disease
 

Am J Gastroenterol. 2022 Jun 1;117(6):927-930. doi: 10.14309/ajg.0000000000001726.Epub 2022 Mar 14.

Eleonora Scorletti 1 2, Kate Townsend Creasy 1, Marijana Vujkovic 1, Mara Vell 2 3, Inuk Zandvakili 1 4, Daniel J Rader 1 4, Kai Markus Schneider 3 5, Carolin V Schneider 1 4
 
208.Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
 

JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477. eCollection 2022 May.

Aidan J McGlinchey 1, Olivier Govaere 2, Dawei Geng 3, Vlad Ratziu 4, Michael Allison 5, Jerome Bousier 6, Salvatore Petta 7, Claudia de Oliviera 8, Elisabetta Bugianesi 9, Jörn M Schattenberg 10, Ann K Daly 2, Tuulia Hyötyläinen 3, Quentin M Anstee 2 11, Matej Orešic 1 12
 
209.Endothelial Dysfunction in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
 

Life (Basel). 2022 May 11;12(5):718. doi: 10.3390/life12050718.

Panagiotis Theofilis 1, Aikaterini Vordoni 1, Nikolaos Nakas 2, Rigas G Kalaitzidis 1
 
210.Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
 

Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-e185.doi: 10.1161/ATV.0000000000000153. Epub 2022 Apr 14.

P Barton Duell, Francine K Welty, Michael Miller, Alan Chait, Gmerice Hammond, Zahid Ahmad, David E Cohen, Jay D Horton, Gregg S Pressman, Peter P Toth, American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease
 
211.Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography
 

Clin Gastroenterol Hepatol. 2022 May;20(5):e1149-e1156. doi: 10.1016/j.cgh.2021.08.038.Epub 2021 Aug 28.

Zobair M Younossi 1, Sean Felix 2, Thomas Jeffers 2, Elena Younossi 2, Brian Lam 2, Fatema Nader